Education
About Us
Working with TipRanks
Follow Us
Vicore Pharma Holding AB (SE:VICO)
:VICO
RESEARCH TOOLSreports
Top Page
Vicore Pharma Holding AB
(Frankfurt:VICO)
45Neutral
Vicore Pharma Holding AB (VICO) vs. S&P 500 (SPY)
Market Cap
kr1.85B
Dividend YieldN/A
Average Volume (3M)338.60K
Price to Earnings (P/E)―
Beta (1Y)0.40
Revenue GrowthN/A
EPS Growth63.85%
CountrySE
Employees29
SectorHealthcare
Sector Strength60
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.44
Shares Outstanding234,579,120
10 Day Avg. Volume480,567
30 Day Avg. Volume338,597
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Vicore Pharma Holding AB Business Overview & Revenue Model
Company DescriptionVicore Pharma Holding AB (VICO) is a Sweden-based pharmaceutical company focused on the development of innovative therapies for rare lung diseases and related indications. The company's core products are centered around its proprietary angiotensin II type 2 receptor (AT2R) agonist platform, which aims to address unmet medical needs in pulmonary and fibrotic diseases. Vicore Pharma's lead product candidate, VP01 (C21), is being developed for conditions such as idiopathic pulmonary fibrosis (IPF) and COVID-19-induced acute respiratory distress syndrome (ARDS).
How the Company Makes MoneyVicore Pharma Holding AB generates revenue primarily through the development and potential commercialization of its pharmaceutical candidates. The company's revenue model is largely dependent on the successful progression of its drug candidates through clinical trials, leading to potential licensing agreements, partnerships, or direct sales of approved therapies. Key revenue streams include milestone payments and royalties from strategic collaborations with larger pharmaceutical companies. Vicore Pharma may also seek funding through grants and public or private investments to support its research and development activities.
Vicore Pharma Holding AB Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 109.35M | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| 109.35M | -3.42M | -3.61M | -3.60M | -3.54M | EBIT |
| -194.19M | -321.51M | -290.73M | -294.82M | -149.54M | EBITDA |
| -168.88M | -317.47M | -286.20M | -293.13M | -143.77M | Net Income Common Stockholders |
| -168.63M | -310.94M | -288.42M | -296.48M | -146.86M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 1.16B | 482.77M | 261.74M | 371.20M | 318.62M | Total Assets |
| 1.20B | 497.84M | 338.01M | 451.17M | 406.51M | Total Debt |
| 0.00 | 0.00 | 65.00K | 320.00K | 140.00K | Net Debt |
| -1.16B | -333.62M | -256.74M | -293.88M | -248.48M | Total Liabilities |
| 73.78M | 42.45M | 48.92M | 67.85M | 52.00M | Stockholders Equity |
| 1.13B | 455.39M | 289.08M | 383.32M | 354.51M |
| Cash Flow | Free Cash Flow | |||
| -164.95M | -448.62M | -302.92M | -265.17M | -122.94M | Operating Cash Flow |
| -164.95M | -249.58M | -299.92M | -265.17M | -119.94M | Investing Cash Flow |
| 149.04M | -144.46M | 74.00M | -7.00M | 4.00M | Financing Cash Flow |
| 834.06M | 470.86M | 187.04M | 318.18M | 176.97M |
Vicore Pharma Holding AB Technical Analysis
Neutral
7.87
Price Trends
7.38
Positive
7.96
Negative
9.36
Negative
Market Momentum
0.26
Negative
57.27
Neutral
77.24
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:VICO, the sentiment is Neutral. The current price of 7.87 is above the 20-day moving average (MA) of 7.14, above the 50-day MA of 7.38, and below the 200-day MA of 9.36, indicating a neutral trend. The MACD of 0.26 indicates Negative momentum. The RSI at 57.27 is Neutral, neither overbought nor oversold. The STOCH value of 77.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:VICO.
Vicore Pharma Holding AB Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | kr1.12B | 5.10 | 179.17% | ― | 1887.36% | ― | |
54 Neutral | kr2.19B | ― | -45.80% | ― | -0.57% | -39.92% | |
52 Neutral | $5.24B | 3.76 | -41.88% | 2.85% | 17.01% | 0.78% | |
50 Neutral | kr2.01B | ― | ― | 9.53% | 41.19% | ||
48 Neutral | kr1.05B | ― | -43.97% | ― | ― | 67.70% | |
47 Neutral | €1.05B | ― | -42.78% | ― | ― | -19.44% | |
45 Neutral | kr1.85B | ― | -20.96% | ― | ― | 63.85% |
* Healthcare Sector Average
Performance Comparison
SE:VICO
Vicore Pharma Holding AB
7.87
-11.49
-59.35%
SE:HNSA
Hansa Biopharma AB
26.26
-4.36
-14.24%
SE:BINV
BioInvent International AB
32.25
6.15
23.56%
SE:SANION
Saniona AB
8.15
6.36
355.82%
SE:XSPRAY
Xspray Pharma AB
35.40
-6.65
-15.80%
SE:SYNACT
SynAct Pharma AB
21.35
14.16
196.98%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.